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We read with interest the paper by Parodi et al. (1) in a previous
issue of the Journal. The authors found that prasugrel and ticagrelor
provided an effective platelet inhibition 2 h after the loading dose in
only half of the patients with ST-segment elevation myocardial
infarction treated with percutaneous coronary intervention, and at
least 4 h were required to achieve an effective platelet inhibition in
the majority of patients.
Although their ﬁndings are interesting, other factors involved in
platelet reactivity have not been completely evaluated. It should be
noted that the individual platelet response to antiplatelet therapy
depends on a network of mechanisms, including genetic factors,
cellular factors (accelerated platelet turnover, reduced cytochrome
CYP3A metabolic activity, increased adenosine-diphosphate expo-
sure, up-regulation of P2Y12 pathways), clinical factors (age, dia-
betes, body mass index, left ventricle ejection function,
inﬂammation, elevated plasma ﬁbrinogen, extent of coronary artery
disease [CAD], number and complexity of CAD lesions, creatinine
clearance, comorbidities, noncompliance, underdosing, poor
absorption, drug-to-drug interactions, smoking), and environmentalfactors (geographic origin) (2–4). In this setting, we have investi-
gated the effect of theCYP2C19 polymorphism on platelet reactivity,
vascular function, and cardiovascular outcome in patients with
CAD.We found that that the CYP2C19*2 polymorphism is a factor
associated with a higher rate of major adverse cardiovascular events
and signiﬁcantly increased platelet reactivity units (PRU) (5,6). Our
ﬁndings indicate that genetic factors play an important role in PRU
and prognosis.
Moreover, in another study, in patients treated with percutaneous
coronary intervention, baseline PRU values are inﬂuenced by several
confounding factors, especially acute atherothrombotic events and
inﬂammation (7). Parodi et al. (1) concluded that the independent
predictors of high residual platelet reactivity at 2 h were morphine
use and baseline PRU value, but we believe that the total appraisal
must also admeasure the contribution of other factors, such as the
severity of myocardial infarction and inﬂammation, which affects
platelet reactivity, in the prediction of high residual platelet reactivity
at 2 h.
Thus, the precise deﬁnition of multiple genetic, cellular, and
clinical determinants inﬂuencing platelet reactivity will lead to
a more individualized and effective adjustment of antiplatelet
treatment for acute myocardial infarction, coronary stenting, and
cardiovascular outcome.
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